Abstract
Aim: To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded. Results: The median age of 51 patients was 56 (range: 33–75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1–22.6) and median overall survival was 42.5 months (95% CI: 37.2–47.8). Conclusion: Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Advancements in low-grade serous carcinoma of the ovary and peritoneum. Curr. Oncol. Rep. 24(11), 1549–1555 (2022). •• Treatment options in low-grade serous ovarian cancer.
- 2. . Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. 216057 (2023).
- 3. . Low-grade serous carcinoma of the ovary: the current status. Diagnostics 12(2), 458 (2022).
- 4. Low grade serous ovarian cancer–a rare disease with increasing therapeutic options. Cancer Treat. Rev. 112, 102497 (2022).
- 5. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin. Cancer Res. 28(20), 4456–4465 (2022).
- 6. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl Comprehens. Cancer Network 19(2), 191–226 (2021).
- 7. Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer. Int.J.Gynecol.Cancer 30(4), 498–503 (2020).
- 8. Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. NPJ Precis. Oncol. 6(1), 47 (2022). • Describes the molecular characterization of low-grade serous ovarian carcinoma.
- 9. Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J. Pathol. 253(1), 41–54 (2021).
- 10. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet 399(10324), 541–553 (2022).
- 11. . New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocr.-Relat. Cancer 29(1), R1–R16 (2022). •• Discusses the treatment options in low-grade serous ovarian cancer.
- 12. . VEGF in signaling and disease: beyond discovery and development. Cell 176(6), 1248–1264 (2019).
- 13. . Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. Future Oncol. 16(7), 225–246 (2020).
- 14. . The utilization of bevacizumab in patients with advanced ovarian cancer: a systematic review of the mechanisms and effects. Int. J. Mol. Sci. 23(13), 6911 (2022).
- 15. . Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience. Gynecol. Oncol. 145(1), 37–40 (2017). • Discusses the efficacy of bevacizumab in low-grade serous ovarian cancer.
- 16. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Int. J. Gynecol. Cancer 24(6), 1010–1014 (2014). •• Discusses the efficacy of bevacizumab in low-grade serous ovarian cancer.
- 17. . Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol. Oncol. 102(1), 5–7 (2006).
- 18. Encouraging responses with bevacizumab in recurrent low-grade serous ovarian cancer. J. Clin. Oncol. 28(Suppl. 15), e15503–e15503 (2010).
- 19. . Activity of bevacizumab in patients with low-grade serous ovarian carcinoma. Int. J. Gynecol.Cancer 26(6), 1048–1052 (2016). • Discusses the efficacy of bevacizumab in low-grade serous ovarian cancer.
- 20. Effect of bevacizumab in advanced low grade serous ovarian cancer: data from the MITO 22 trial. Gynecol. Oncol. 172, 72–77 (2023). •• Discusses the efficacy of bevacizumab in low-grade serous ovarian cancer.
- 21. MILO/ENGOT-ov11: binimetinib versus physician's choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J. Clin. Oncol. 38(32), 3753 (2020).
- 22. Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma. Sci. Rep. 13(1), 7681 (2023).
- 23. Adverse events associated with long-term treatment of epithelial ovarian cancer with bevacizumab and chemotherapy. Anticancer Res. 42(8), 4165–4171 (2022).
- 24. A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer. Japan. J. Clin. Oncol. 51(1), 54–59 (2021).
- 25. . Survival in recurrent ovarian cancer patients before and after the bevacizumab era: an observational single-centre study. J. Obstet. Gynaecoly. 42(6), 2230–2234 (2022).